Peer-reviewed veterinary case report
How trilostane affects urine stress hormones in dogs with Cushing's
By Sieber-Ruckstuhl, Nadja et al.·Published in BMC veterinary research·2017·Clinic for Small Animal Internal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of Trilostane on urinary Catecholamines and their metabolites in dogs with Hypercortisolism.
- Species:
- dog
Plain-English summary
A group of dogs with hypercortisolism (Cushing's disease) had their urine tested for certain hormones before and during treatment with a medication called trilostane. The results showed that these dogs had higher levels of epinephrine and norepinephrine compared to healthy dogs, indicating ongoing stress from the condition. Although trilostane did not significantly lower these hormone levels, dogs that had lower cortisol levels after treatment showed slightly better results. This suggests that while trilostane helps manage some aspects of hypercortisolism, it may not fully normalize hormone levels in urine.
People also search for: dog Cushing's disease treatment · trilostane for dogs · high cortisol symptoms in dogs
Abstract
BACKGROUND: Glucocorticoids influence the synthesis and metabolism of catecholamines (epinephrine and norepinephrine) and metanephrines (metanephrine and normetanephrine). The aim of this study was to measure urinary catecholamines and metanephrines in dogs with hypercortisolism before and during trilostane therapy. Urine samples were collected during initial work up and during therapy with trilostane in 14 dogs with hypercortisolism and in 25 healthy dogs. Epinephrine, norepinephrine, metanephrine and normetanephrine were measured using high-pressure liquid chromatography and expressed as ratios to urinary creatinine concentration. RESULTS: Untreated dogs with hypercortisolism had significantly higher epinephrine, norepinephrine, and normetanephrine:creatinine ratios compared to healthy dogs. During trilostane therapy, urinary catecholamines and their metabolites did not decrease significantly. However, dogs with low post-ACTH cortisol concentrations during trilostane therapy had less increased epinephrine, norepinephrine and normetanephrine:creatinine ratios compared to healthy dogs. There was no correlation of urinary catecholamines and their metabolites with baseline or post-ACTH cortisol or endogenous ACTH concentrations during trilostane therapy. CONCLUSION: Influences between steroid hormones and catecholamines seem to occur, as dogs with hypercortisolism have significantly higher urinary epinephrine, norepinephrine, and normetanephrine:creatinine ratios. Once-daily trilostane therapy does not lead to a significant decrease in catecholamines and their metabolites. Trilostane-treated dogs still have increased urinary epinephrine, norepinephrine and normetanephrine:creatinine ratios during trilostane therapy.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28870207/